GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VioQuest Pharmaceuticals Inc (OTCPK:VOQP) » Definitions » Piotroski F-Score

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Piotroski F-Score : 0 (As of May. 25, 2024)


View and export this data going back to . Start your Free Trial

What is VioQuest Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

VioQuest Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for VioQuest Pharmaceuticals's Piotroski F-Score or its related term are showing as below:


VioQuest Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for VioQuest Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VioQuest Pharmaceuticals Piotroski F-Score Chart

VioQuest Pharmaceuticals Annual Data
Trend Dec98 Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

VioQuest Pharmaceuticals Quarterly Data
Sep03 Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun08) TTM:Last Year (Jun07) TTM:
Net Income was -2.882 + -3.019 + -3.081 + -1.131 = $-10.11 Mil.
Cash Flow from Operations was -2.627 + -1.762 + -1.06 + -1.546 = $-7.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Jun07)
to the end of this year (Jun08) was
(5.694 + 3.457 + 1.358 + 0.698 + 1.177) / 5 = $2.4768 Mil.
Total Assets at the begining of this year (Jun07) was $5.69 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $1.13 Mil.
Total Current Liabilities was $2.69 Mil.
Net Income was -1.885 + -2.436 + -2.518 + -2.472 = $-9.31 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Jun06)
to the end of last year (Jun07) was
(5.159 + 3.739 + 5.828 + 3.828 + 5.694) / 5 = $4.8496 Mil.
Total Assets at the begining of last year (Jun06) was $5.16 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $5.64 Mil.
Total Current Liabilities was $5.63 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

VioQuest Pharmaceuticals's current Net Income (TTM) was -10.11. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

VioQuest Pharmaceuticals's current Cash Flow from Operations (TTM) was -7.00. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun07)
=-10.113/5.694
=-1.77608008

ROA (Last Year)=Net Income/Total Assets (Jun06)
=-9.311/5.159
=-1.80480713

VioQuest Pharmaceuticals's return on assets of this year was -1.77608008. VioQuest Pharmaceuticals's return on assets of last year was -1.80480713. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

VioQuest Pharmaceuticals's current Net Income (TTM) was -10.11. VioQuest Pharmaceuticals's current Cash Flow from Operations (TTM) was -7.00. ==> -7.00 > -10.11 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun08)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun07 to Jun08
=0/2.4768
=0

Gearing (Last Year: Jun07)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun06 to Jun07
=0/4.8496
=0

VioQuest Pharmaceuticals's gearing of this year was 0. VioQuest Pharmaceuticals's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun08)=Total Current Assets/Total Current Liabilities
=1.132/2.694
=0.42019302

Current Ratio (Last Year: Jun07)=Total Current Assets/Total Current Liabilities
=5.643/5.633
=1.00177525

VioQuest Pharmaceuticals's current ratio of this year was 0.42019302. VioQuest Pharmaceuticals's current ratio of last year was 1.00177525. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

VioQuest Pharmaceuticals's number of shares in issue this year was 4.905. VioQuest Pharmaceuticals's number of shares in issue last year was 4.606. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

VioQuest Pharmaceuticals's gross margin of this year was . VioQuest Pharmaceuticals's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun07)
=0/5.694
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun06)
=0/5.159
=0

VioQuest Pharmaceuticals's asset turnover of this year was 0. VioQuest Pharmaceuticals's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

VioQuest Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

VioQuest Pharmaceuticals  (OTCPK:VOQP) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


VioQuest Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of VioQuest Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 2287, Minneapolis, MN, USA, 55402
Website
VioQuest Pharmaceuticals Inc is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment.
Executives
Mark D Dacko director, officer: CFO and Secretary 800 NICOLLET MALL SUITE 2690, MINNEAPOLIS MN 55402
Christopher P. Schnittker officer: V.P. & Chief Financial Officer 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Brian Lenz officer: CFO and Treasurer 65 COMMERCE WAY, HACKENSACK NJ 07601
Lau Johnson Yiu Nam director
Michael Weiser director C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Stephen Rocamboli director, officer: Secretary C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Daniel E Greenleaf director, officer: President and CEO C/O NABI BIO PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD., N.W., BOCA RATON FL 33487
Lester E Lipschutz 10 percent owner WOLF BLOCK SCHORR AND SOLIS COHEN, 1650 ARCH STREET, PHILADELPHIA PA 19103
David M Tanen director TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Headlines

No Headlines